Mesoblast (ASX:MSB) Margin of Safety % (DCF Dividends Based): N/A (As of Jun. 28, 2026)


ASX:MSB Mesoblast Ltd ASX:MSB
46 GF Score
Price A$1.89
! 4 Warning Signs
View Full Analysis

What is Mesoblast Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Mesoblast's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

ASX:MSB vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Mesoblast's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Mesoblast's Margin of Safety % (DCF Dividends Based) falls into.


ASX:MSB
46GF Score
Mesoblast Ltd ASX:MSB
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score

Get the complete analysis for ASX:MSB

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.89
Price